jilino1 online slot game
HALIFAX — Former Halifax mayor Mike Savage has been sworn in as Nova Scotia’s 34th lieutenant-governor. Savage was installed during a ceremony today at the Nova Scotia legislature. Prime Minister Justin Trudeau announced Savage’s appointment as the King’s representative in Nova Scotia in October. He replaces Arthur J. LeBlanc who had held the position since 2017 and who carried out his last official function on Thursday, presiding over the swearing in of the provincial government’s new cabinet. Savage served 12 years as mayor of Atlantic Canada’s largest city and announced in February that he wouldn’t seek re-election. Previous to becoming mayor, Savage served for seven years as the MP for the federal riding of Dartmouth-Cole Harbour. This report by The Canadian Press was first published Dec. 13, 2024. The Canadian Press
NASSAU, Bahamas — Scottie Scheffler birdied every hole but the par 3s on the front nine at Albany Golf Club on Friday and finished his bogey-free round with an 8-under 64 that gave him a two-shot lead in the Hero World Challenge. Two months off did nothing to slow the world's No. 1 player. Scheffler already has eight victories this year and is in position to get another before the end of the year. Scheffler was at 13-under 131, two ahead of Akshay Bhatia (66) and Justin Thomas (67), both of whom had to save par on the 18th hole to stay in range going into the weekend. Scheffler started with a lob wedge to 2 feet for birdie and never slowed until after he went out in 29 to seize control of the holiday tournament against a 20-man field. Scheffler cooled slightly on the back nine, except it didn't feel that way to him. “Front nine, just things were going my way. Back nine, maybe not as much,” Scheffler said. “A couple shots could end up closer to the hole, a couple putts go in, just little things.” Asked if he felt any frustration he didn't take it lower — he once shot 59 at the TPC Boston during the FedEx Cup playoffs — Scheffler sounded bemused. “I think in this game I think a lot of all y’all are looking for perfection out of us,” he said. “Today I shot 8 under on the golf course, not something I hang my head about. A lot of good things out there — clean card, bogey-free, eight birdies. Overall, I think I'm pretty pleased.” Thomas felt his 67 was stress-free, particularly the way he was driving the ball. The wind laid down again, rare for the Bahamas, though it is expected to pick up on the weekend. Thomas wasn't concerned to see Scheffler get off to a hot start, especially with three par 5s on the front nine and a short par 4 that at worst leaves a flip wedge to the green. “You literally can birdie every hole as soft as the greens are,” Thomas said. “He's a great player, a great wedge player, and you have a lot of birdie holes to start. I'm honestly surprised he only shot 8 under. It's a sneaky course because if you fall asleep on some shots, you can get out of position. But if you're on and focused and really in control of everything — like these last two days with no wind — you can just make so many birdies.” Ryder Cup captain Keegan Bradley had a 67 and was four shots behind. No matter how benign the conditions, it wasn't always easy. Cameron Young, who opened with a 64 for a two-shot lead, followed with a 75 despite making five birdies. That included a double bogey on the final hole when his approach tumbled down the bank into the rocks framing the lake that goes all the way down the 18th hole. Patrick Cantlay was trying to keep pace playing alongside Scheffler, but he had three bogeys over the final seven holes and fell seven shots behind with a 71. The tournament, hosted by Tiger Woods, is unofficial but offers world ranking points to all but the bottom three players because of the small field. It's the weakest field in 25 years, but Scheffler at No. 1 gives it enough cachet. He is the first player since Woods in 2009 to start and finish a year at No. 1 in the world. And even after a layoff — giving him time to tinker with a new putting stroke — it looks like it might be a while before anyone changes that. AP golf: https://apnews.com/hub/golfKitchens will lead Tar Heels in Fenway Bowl against UConn. Another ex-Browns coach is standing byElon Musk spent over a quarter of a billion dollars to help Donald Trump win November's presidential election, according to new filings, underscoring the influence one of the world's wealthiest people had on this year's White House race. The billionaire owner of electric car maker Tesla and SpaceX gave $259 million to groups supporting Trump's 2024 campaign, according to new Federal Election Commission filings released late on Thursday. The huge donations made Musk one of the biggest underwriters of a presidential campaign in U.S. history, helping him to become a powerful political ally of Trump and someone who now plays a key role in shaping the incoming Republican administration's policy agenda. Musk gave $239 million to America PAC, a super PAC he founded to help turn out voters for Trump. In late October Musk gave an additional $20 million to RBG PAC, a group that sought to convince voters that Trump would not sign into a law a national abortion ban, according to the FEC filings. The group's name refers to the late Supreme Court Justice Ruth Bader Ginsburg, a liberal icon known for her support of abortion rights. Musk, who also owns the social media platform X, has emerged as a close advisor in Trump's transition team. Trump has chosen him, along with former Republican presidential candidate and entrepreneur Vivek Ramaswamy, to head a task force aimed at slashing government spending and regulations. Musk and Ramaswamy met on Capitol Hill on Thursday with lawmakers whose support they will need to win the sweeping spending cuts Trump has asked them to find. The two men have called for firing thousands of federal workers, slashing regulations and eliminating programs whose authorization has expired, such as veterans' healthcare. Musk has also been a regular fixture and Trump confidante at the president-elect's Mar-a-Lago Florida estate during the transition. (Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.) Track Latest News Live on NDTV.com and get news updates from India and around the worldANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 Investors@transmedics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-2024-financial-outlook-302320060.html SOURCE TransMedics Group, Inc.
Freiburg survives late onslaught to beat Wolfsburg in Bundesliga thrillerScottie Scheffler goes on a run of birdies in the Bahamas and leads by 2Welcome to Startups Weekly — your weekly recap of everything you can’t miss from the world of startups. Want it in your inbox every Friday? Sign up here . The week after Thanksgiving is usually rich in announcements, and this year was no exception. Blame it on the holiday season, but we would even go as far as saying that several funding round announcements were truly heartwarming. Most interesting startup stories from the week This week brought us a new company to track closely, salary insights, a bunch of new YC grads, and more. New page : Three members of Google’s NotebookLM team left the company to create their own startup , following in the footsteps of AI pioneer François Chollet . Pay gaps : Kruze Consulting, a CPA firm that specializes in venture-backed startups, shared insights on the average salary of early employees and confirmed that the Bay Area still commands higher figures. There, very senior engineers enter seed startups with salaries ranging from $180,000 to $235,000, compared to $160,000 to $210,000 in other areas. Arm wrestling : Fitness startup Ladder, which recently raised $105 million in Series B funding, pointed out similarities between its strength-training app and Peloton’s new Strength+ app, turning it into a marketing and advertising opportunity of its own. Back IRL : As announced, Y Combinator’s latest Demo Day for its Fall 2024 class of startups took place in person . Most interesting fundraises this week This week, we have funding news about several startups working on big problems — and one allegedly making popcorn. Clean atmosphere : Heirloom Carbon secured $150 million in Series B funding to help scale up its carbon-capture technology. Heart health : Cleerly, a cardiovascular imaging startup, is applying AI to detect coronary artery disease early on and raised a $106 million Series C extension round to keep on working toward this mission. Fighting cancer : Orakl Oncology, a French lab spinoff that combines data and biology to bring new drugs to cancer patients, raised nearly €15 million to date , including nondilutive funding from Bpifrance and more recently, an equity round led by European VC fund Singular. Fighting fires : Named after Israel’s Iron Dome missile defense system, FireDome, a startup that uses projectiles filled with fire retardants to stop wildfires, raised a $3 million pre-seed round led by Third Sphere and Gravity Climate. Popcorn time : According to an SEC filing, Khloé Kardashian and Kris Jenner are looking to raise $10 million for Khloud , a consumer startup that is rumored to be a protein popcorn brand. Most interesting VC and fund news this week Scoring again : Former NBA athlete Omri Casspi raised $60 million for his new venture fund, Swish Ventures , which will back cybersecurity, cloud infrastructure, and AI startups. The Israeli player previously launched $36 million fund Sheva Capital, whose investment period has concluded. Going public : Dutch investment group Prosus expects five potential IPOs from its Indian portfolio over the next 18 months. This would represent a significant share of the 20 Indian startups that are looking to go public in 2025. Time for funding : French VC firm Daphni teamed up with partners to launch Time4 , a fund with a target of €100 million and a mandate to invest in entrepreneurs with diverse backgrounds and impactful projects. Last but not least Voyager Ventures investment director Leonardo Banchik and other climate tech investors are cautiously optimistic about policy changes being considered by the second Trump administration . These won’t be universally detrimental to the sector, and some might even stand to benefit climate tech, TechCrunch heard.
Should AI resurrect extinct species like Neanderthals?
Tweet Facebook Mail Luigi Mangione, the clean-cut 26-year-old accused of killing UnitedHealthcare chief executive Brian Thompson in New York City, has gained a fervent fan base of social media users hailing him as a hero and a heartthrob. The New York Police Department released surveillance images of the man they suspect had brazenly killed Thompson on a busy street in Midtown Manhattan on December 3 as part of their five-day manhunt across several states. They appealed to the public for their assistance but, instead, the pictures set off an internet frenzy of users complimenting his appearance. READ MORE: Australian teen 'stabbed to death' in Thailand A man alleged to be Luigi Mangione smiles in surveillance footage released after the shooting. (AP) "He was just demonstrating the true power of having 'looks that could kill'. The only thing criminal is his bone structure," one user said. Officials revealed the words "depose", "deny" and "delay" had been written on bullet casings found at the scene, which seemingly point to Jay Feinman's book Delay, Deny, Defend on tactics used by insurers to deny claims. A tip earlier this week led police to arrest Mangione, an Ivy League graduate from a prominent family who is believed to have targeted Thompson. His motive remains unknown. This photo provided by Pennsylvania State Police shows Luigi Mangione, the suspect in the fatal shooting of UnitedHealthcare CEO Brian Thompson, at the police station in Altoona, Pennsylvnia after his arrest. (AP) Despite now facing a murder charge, the public has been overwhelmingly supportive and even branded him a hero in light of criticisms of the country's healthcare system. Mangione's lawyer, Tom Dickey, told CNN that some people had even offered to help pay his legal fees. "He went against private health insurance corporations is what he did ... And in this house, Luigi Mangione is a hero, end of story," one user said, summing up much of the sentiment online. Another said: "The main difference being Luigi Mangione allegedly killed one person while the Insurance CEO killed thousands of people for profit." READ MORE: Gasps as notorious killer 'excluded' from DNA evidence A report by the Network Contagion Research Institute recorded a surge of highly engaged social media posts glorifying the incident with six of the top 10 posts expressing explicit or implicit support for the killing. "The thing that's odd about about this case is that you've got someone who's committed a horrible crime and yet he seems to have this positive image," Monash University senior media lecturer Andy Ruddock told 9news.com.au. Ruddock said the link between Mangione's support and the frustration of the US healthcare industry is undeniable and pointed to the phrase "desk killers", which refers to someone who indirectly assists in killings through clerical tasks. "People have felt comfortable being as callous as the health industry appears to be," he said. "It does seem to me that people are kind of saying, 'We know what we're doing and this is why we're doing it', and it's also become an event around which people are quite clearly talking about the savageness of the denial of healthcare." READ MORE: Young Australians have highest rates of bowel cancer in the world Luigi Mangione is escorted into Blair County Courthouse in Hollidaysburg, Pennsylvania. (AP Photo/Gary M. Baranec) UnitedHealthcare chief executive officer Brian Thompson was shot dead as he walked to an investor conference in Manhattan. (UnitedHealth Group) Ruddock said that Mangione's popularity could also be explained by the historical glamorisation of vigilantes and killers, as well as the media storytelling and interest around figures like Robin Hood, Bonnie and Clyde and Ted Bundy. "If you think about someone like Ted Bundy, where people would talk about this serial killer who nevertheless had this curious charm, there are a lot of similarities there because we're talking about someone most people thought was a good-looking guy, well-educated," he said. "We have a number of mythic stereotypes. (Mangione) makes sense from those points of view and then we have the social media use being layered over the top of that." Mangione's looks and Ivy League background have only added to his appeal, Ruddock said. "It's breaking expectations about who would commit these sorts of crimes," he said. READ MORE: 'Human trash': Vandals target police memorial site Ruddock said these types of alleged killings represent a "reversal of power" of someone who may appear to be "untouchable", adding that there is an increased approval for violence if it is exercised for political reasons. "If we think about Trump returning to the presidency, what do we see there? We see political violence being rewarded. There's the insurrection of January the 6th," he said. "It's different directions but the same type of logic." But the reality is that an act of violence occurred and a man is dead, Ruddock said. "There's the reality and the reality of the way it is being narrated," he said. Luigi Mangione in arrest photos supplied by US police. (Nine) The case has been polarising, according to Altoona Deputy Police Chief Derek Swope, who said his officers have been receiving threats from the community. Mangione is facing charges in New York and extradition from his jail cell in Pennsylvania. Social media users are now providing false alibis for Mangione, only fuelling his support. Timeline of a manhunt: How police tracked down alleged CEO assassin View Gallery DOWNLOAD THE 9NEWS APP : Stay across all the latest in breaking news, sport, politics and the weather via our news app and get notifications sent straight to your smartphone. Available on the Apple App Store and Google Play .
Tables quickly turned against Tyson Fury (34-1-1, 24 KOs) during his fight against Oleksandr Usyk (22-0, 14 KOs). In a few days, ‘The Gypsy King’ will face the ‘The Cat’ once again for a highly anticipated rematch at the Kingdom Arena in Riyadh, Saudi Arabia. Their first fight saw Fury suffer the first loss of his professional career. However, Fury feels he had the upper hand for most of the fight. The recently released Oleksandr Usyk vs. Tyson Fury 2: Witnessing Greatness preview documentary saw the former champ delve into the nuances of the fight. And the areas where he let his confidence get the best of him. “85 percent of the fight, it was one way. It was more like me punching around the body and around the head at will. And having me way, quite comfortable ,” he said. This, however, instilled in him a heightened sense of confidence. And, as the cameras stood witness, Usyk started showboating, being the “jolly giant” that he is. While it went well for him initially, things quickly took a turn for the worse. “I didn’t feel like I was in a position of danger. One of the commentators picked it up and said, ‘Has anyone seen Tyson Fury clown this much?’ in a fight, even at the lower level. And no one did because it was the most I was playing games. And I ended up paying the price for it later on in the fight,” h e said. Fury seemed the most comfortable between rounds 3 and 6, and it seemed like victory was just a timely knockout away. However, he was not ready for the punishment that Usyk dished out during the ninth round, which turned out to be pivotal for the fight. The following rounds were no different, which, in turn, made Usyk the winner by decision. “Tyson’s Mindset Has Changed” Many members of the fraternity have voiced their concerns about a shift in Fury’s mindset during the first fight. In fact, Joseph Parker feels that Fury will only have a chance at winning the fight against Usyk if he changes his mindset. “I feel like the first fight was very back and forth. I think Tyson’s mindset has changed coming into this fight,” he said. “I feel that if you have a different mindset, that can bring a lot of changes. I believe Tyson can beat Usyk on a points decision, but it’s a tough one. I’m siding with Tyson, but I think it’s a points decision.” This article first appeared on Fights Around The World and was syndicated with permission.Brian Callahan explains why Titans abandoned early season philosophy on offense
Canadian Apartment Properties Real Estate Investment Trust Un stock falls Friday, underperforms marketBrian Callahan explains why Titans abandoned early season philosophy on offenseThis holiday season, be thankful for the taxpayer protections we have in California